None listed
Conditions
Interventions
5 mg BMS-298585 Type of group
Double-blind treatment will be administered with BM.S-29.8585 orally plus metformin.
Group name:placebo Type of group
Double-blind treatment with placebo will be administered orally plus metformin.
Sponsors
BRISTOL MYERS SQUIBB COMPANY,
Eligibility
Inclusion criteria
Inclusion criteria: 1) Body Mass Index 7.0% and 1.5 ng / mL. 5) average serum TG 600 and <1000 mg / dL, can make a new determination).
Exclusion criteria
Exclusion criteria: 1) Symptomatic type 2 diabetes, defined by polyuria and poiidipsia with loss weighing more than 10% during the last three months. 2) History of diabetic ketoacidosis, hyperosmolar non-ketotic coma, or insulin treatment within one year of selection. 3) Individuals who have contraindications to treatment as described explained in the Instructions for the Researcher of BI \ / IS-298585 or in the package insert for metformin.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Outcome name:HbA1c Measure:Change in baseline HbA1c in Week 24 (or in the last post-baseline measurement prior to that Week, if the evaluation of Week 24 is not available), during the double-blind, short-term phase. Timepoints:24 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| Outcome name:CRP Measure:Change in the value of high sensitivity C-reactive protein between its baseline level and that of Week 24, or in the last post-baseline measurement prior to that Week, if the evaluation of Week 24 is not available. Timepoints:24 weeks | — |
Countries
Australia, Canada, France, Korea North, Mexico, Poland, Sweden, United Kindgdom, United States
Outcome results
None listed